Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Aware is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 14 original sources per story, versus 2.8 across the same-window beat baseline.
Last mentioned: Mar 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Aware is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 14 original sources per story, versus 2.8 across the same-window beat baseline. The 6 average consequence score is above the beat benchmark of 5.8 in the same window. Glendon French appears in 1 tracked Healthcare story from March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Glendon French. Shared-story counts are live from our verified record — not editorial picks.
Stevanato Group reported robust 2025 results fueled by a 50% surge in GLP-1 related revenue, while medical device maker Pulmonx initiated aggressive cost-cutting measures following a U.S. revenue decline. The divergence highlights a shifting healthcare landscape where specialized biopharma supply chains are outperforming traditional niche medical devices.
Glendon French is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
